Abstract

4SCAR2.0 Treating Refractory B Cell Lymphomas: An advanced Technology Saves More Lives!

CAR-T cell therapy represents an innovative and effective therapy forpatientswithrefractory/relapsed Bcellmalignancies. However, many limitations remain with the currently approved CAR-T products, including antigen escape, CAR-T exhaustion in vivo, significant toxicity, and high cost, to name a few.


Author(s):

Cheng Jiao, Liyuan Sheng and Lung-Ji Chang



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+